Phase 2 trial for hematological CR patients of AML after chemotherapy.

Phase 2 trial for hematological CR patients of AML after chemotherapy. - Phase 2 trial for hematological CR patients of AML after chemotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015870

Enrollment

Registered

2014-12-08

Start date

2011-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

WT1 peptide vaccine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AML patients who archive the hematological CR after chemotherapy. The main organ fucntion is OK. (AST<normal limit*4, ALT<normal limit*4, T-bil<2.0mg/dl, Cr<2.0mg/dl,ECG is OK, SpO2>94%) HLA-A is A0201 or A2402. Hematopoietic function recovers over below. (Neu>1000, Plt>50.000, Hb 7.0)

Exclusion criteria

Exclusion criteria: AML associated with MPD double cancer active infection post hematological stem cell transplantation

Design outcomes

Primary

Measure	Time frame
1 year OS, 2 year OS 1 year DFS, 2 year DFS	—

Countries

Japan

Contacts

Public ContactJun Nakata

Osaka University Cancer Immunotherapy

clinical-trial@cit.med.osaka-u.ac.jp06-6879-3676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026